StockWatch
·

Rubicon Research Ltd Q2 FY27 Results

RUBICONQ2 FY27 Results
Filing
Result:Very Good· Market: Crashed#Margin expansion#Record quarter
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue576.387.9%39.9%
Total Income578.677.2%40.2%
Expenditure461.757.5%35.4%
PBT116.925.9%63.1%
Net Profit90.436.7%67.9%
OPM25.00%0.84pp2.11pp
NPM15.63%0.07pp2.58pp
EPS5.476.6%56.7%
View full financials

Pharma core metrics—revenue +39.9% and adjusted PAT +67.9% YoY—came with genuine margin expansion (OPM 25.0% vs 22.89% YoY and up from 24.16% QoQ) and a record/5-quarter-high print, a clear sector standout though partly aided by the Arinna acquisition since standalone growth was a milder 14%/32.3%.

Q2 FY-2027 RESULTS · RUBICON

Rubicon Research Q2FY27: consolidated PAT +68% YoY to ₹90.4 Cr, OPM expands to 25%

PAT +67.9% YoY · revenue +39.9% · margins expanding

05 Nov 2026 · 3 min read
Revenue

₹576.38 Cr

+39.9% YoY

PAT (consolidated)

₹90.43 Cr

+67.9% YoY

Net margin

15.63%

+2.6pp YoY

EPS

₹5.47

Rubicon Research's consolidated PAT rose 67.9% YoY to ₹90.43 Cr (₹53.85 Cr a year ago) on revenue of ₹576.38 Cr, up 39.9% YoY (₹412.02 Cr) — profit growing well ahead of sales, the clearest sign of operating leverage this quarter. Sequentially the move was more modest (revenue +7.9% QoQ, PAT +6.7% QoQ, off a strong ₹534.34 Cr/₹84.78 Cr Q1 FY27 base), so the YoY print, not the QoQ step-up, is the real story here.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹576.38 Cr+7.9%+39.9%
Expenses₹461.75 Cr+7.5%+35.4%
PAT₹90.43 Cr+6.7%+67.9%
Net margin15.63%-0.1pp+2.6pp
EPS₹5.47+6.6%+56.7%

The margin bridge: operating margin (EBITDA/revenue from operations, consistent with how OPM is tracked for this company) expanded to ~25.0% from 24.16% in Q1 FY27 and 22.89% a year ago — sequential and YoY expansion both. Net margin held near-flat QoQ at 15.6% (vs 15.70% in Q1) but is up roughly 260 bps YoY from 13.05%, helped by a lower effective tax rate (22.7% this quarter vs 24.97% a year ago), which let PAT (+67.9% YoY) outgrow PBT (+63.5% YoY). Standalone — the India-only entity — printed PAT of ₹60.62 Cr (+32.3% YoY) on revenue of ₹383.57 Cr (+14.0% YoY), both far behind the consolidated pace; that >25-point growth gap is structural, not a reporting inconsistency, since the consolidated base now carries Arinna Lifesciences (85% stake, acquired April 30, 2026) and the international subsidiary network that standalone excludes.

₹
1,368.251,504.521,640.81,777.081,913.351,74008-0308-2509-1710-1211-0411-05Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹1,740, up 9% over the past month of trading.

₹ Cr
033.7667.52101.2853.85Q2 FY26rev ₹412 Cr72.8Q3 FY26rev ₹476 Cr76.79Q4 FY26rev ₹514 Cr84.78Q1 FY27rev ₹534 Cr90.43Q2 FY27rev ₹576 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the highest quarterly PAT in the last 5 quarters on our records; PAT has now risen for 4 consecutive quarters; revenue is at a 5-quarter high.

Beyond the headline

What the summary numbers don't show

EPS: consolidated basic ₹5.47 (diluted ₹5.41) vs ₹5.13 in Q1 FY27 and ₹3.49 a year ago

What management guided (1 FY-2027 call)
EBITDA margin ~23% for FY27 (upgraded from 22-23% band). ₹500 Cr R&D spend over 9 quarters (on track: ₹251 Cr in 5 qtrs). Pithampur commercialization Q1 CY2027; New Jersey facility CY2027. Q2 tracking strong sequential USD growth.

— This quarter: beat

Against management's own prior guidance (Aug 19, 2026 concall): the ~23% FY27 EBITDA margin target (itself an upgrade from a 22-23% band) is already being cleared on a single-quarter basis at 25.0% OPM. R&D spend of ₹64.66 Cr this quarter (₹124.73 Cr for H1 FY27, consolidated) is tracking consistently with the ₹500 Cr/9-quarter commitment management flagged as on-track in August. The New Jersey manufacturing facility AdvaGen Holdings acquired this quarter (~USD 2.9 mn) sits ahead of the CY2027 commercialization guidance for that site, while Pithampur's Q1 CY2027 target has no update in this filing. No management press release was available in the context for this result, so the notes to accounts are the only company commentary — they cover the pending Kia Health Tech amalgamation (filed Aug 3, 2026, not yet effective) and IPO-proceeds utilisation (₹406.68 Cr of ₹471.27 Cr net proceeds used, balance timeline extended to March 2027). No quarter-specific Street consensus for PAT/revenue could be located via search — only FY27 full-year revenue consensus (~₹2,320 Cr) and price-target data turned up — so the print cannot be graded against a specific estimate this quarter.

  • W1

    USFDA Ambernath inspection outcome (began Oct 30, 2026) and classification of the 1-observation Satara inspection (Oct 9, 2026) — both unresolved at filing

  • W2

    Whether the ~23% FY27 EBITDA margin guidance holds as a full-year average against the 25.0% OPM clocked this quarter

  • W3

    R&D spend pace against the ₹500 Cr/9-quarter target (₹124.73 Cr consolidated spent in H1 FY27) and the Pithampur (Q1 CY2027)/New Jersey (CY2027) commercialization timelines

Both statements clean and fully legible (Deloitte limited-review, no exceptional-item line); consolidated PAT includes ₹(0.52) mn attributable to minority interest (owners' PAT ₹90.478 mn) following the Arinna Lifesciences 85% stake acquisition (Apr 30, 2026) — this inorganic addition, not standalone, drives most of the gap between standalone and consolidated growth rates.

Informational and educational content only. Not investment advice.